How do you manage zolbetuximab-associated hypoalbuminemia in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinoma who develop symptomatic edema or ascites?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Are you comfortable using durvalumab + tremelimumab in advanced HCC with portal vein thrombus, when these patients were not included in the HIMALAYA trial?

What are your top takeaways in GI Cancers from ASCO 2026?

For localized resectable dMMR colon cancer, do you think single or doublet immune checkpoint inhibition will become the new standard?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.